 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: A randomized trial by Professor Ming Shi's team from Sun Yat-sen University Cancer Hospital confirmed that the use of FOLFOX for hepatic arterial infusion chemotherapy can significantly prolong the survival of patients with unresectable large liver cancer!

J Clin Oncol: A randomized trial by Professor Ming Shi's team from Sun Yat-sen University Cancer Hospital confirmed that the use of FOLFOX for hepatic arterial infusion chemotherapy can significantly prolong the survival of patients with unresectable large liver cancer!

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

ductal carcinoma

aluminum cause cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In a previous phase II clinical trial, the use of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for hepatic artery infusion chemotherapy (HAIC) resulted in greater than transarterial chemoembolization (TACE) in unresectable large hepatocellular carcinoma.
Higher treatment response
.

Shi Ming, director of the Department of Liver Oncology, Sun Yat-sen University Tumor Hospital, led a team to carry out a randomized, multi-center, open-label clinical trial to compare unresectable large liver cancer (tumor diameter ≥ 7cm) The overall survival of the patient
.

Patients with unresectable large liver cancer were randomly assigned to the FOLFOX-HAIC group 1:1 (on day 1 infusion of oxaliplatin 130 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2, followed by infusion of fluorouracil 2400 mg /m2, lasting 24 hours, every 3 weeks treatment course) or TACE group (50 mg epirubicin, 50 mg lobaplatin, lipiodol and polyvinyl alcohol particles)
.

The primary endpoint is overall survival in the intention-to-treat analysis

Evaluate safety in patients receiving ≥ 1 course of study treatment

Overall survival and progression-free survival of the two groups

From October 1, 2016 to November 23, 2018, a total of 315 patients were randomly assigned to the FOLFOX-HAIC group (n=159) or TACE group (n=156)
.

The median overall survival of the FOLFOX-HAIC group and the TACE group were 23.

The occurrence of adverse events in the two groups

In addition, the incidence of serious adverse events in the TACE group was higher than that in the FOLFOX-HAIC group (30% vs 19%; P=0.
03)
.

Two deaths each in the FOLFOX-HAIC group and the TACE group were deemed treatment-related

The incidence of serious adverse events in the TACE group was higher than that in the FOLFOX-HAIC group .

Compared with TACE, FOLFOX-HAIC treatment can significantly prolong the overall survival of patients with unresectable large liver cancer

Original source:

Qi-Jiong Li, et al.

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.